

Umbilical cord mesenchymal stem cells-derived exosomes deliver miR-21 to promote corneal epithelial wound healing through PTEN/PI3K/Akt pathway

Xiaolong Liu

Northeast Agricultural University

Xuran Li

First Affiliated Hospital of Harbin Medical University

Guangyuan Wu

First Affiliated Hospital of Harbin Medical University

Pengfei Qi

First Affiliated Hospital of Harbin Medical University

Yanyan Zhang

First Affiliated Hospital of Harbin Medical University

Zhiyu Liu

First Affiliated Hospital of Harbin Medical University

Xinyue Li

First Affiliated Hospital of Harbin Medical University

Yu Yu

First Affiliated Hospital of Harbin Medical University

Xiangmei Ye

First Affiliated Hospital of Harbin Medical University

Yang Li

First Affiliated Hospital of Harbin Medical University

Dongguang Yang

First Affiliated Hospital of Harbin Medical University

Yueqiu Teng

First Affiliated Hospital of Harbin Medical University

Ce Shi

First Affiliated Hospital of Harbin Medical University

Xin Jin

First Affiliated Hospital of Harbin Medical University

Sen Qi

First Affiliated Hospital of Harbin Medical University

Yuting Liu

First Affiliated Hospital of Harbin Medical University

Shudan Wang

First Affiliated Hospital of Harbin Medical University

Ying Liu

First Affiliated Hospital of Harbin Medical University

Fenglin Cao

First Affiliated Hospital of Harbin Medical University

Qingran Kong

Northeast Agricultural University

Zhenkun Wang (✉ wzkcc@163.com)

First Affiliated Hospital of Harbin Medical University

Hong Zhang

First Affiliated Hospital of Harbin Medical University

Research Article

Keywords: Corneal wound healing, Umbilical cord mesenchymal stem cell, Exosomes, miR-21, PTEN

Posted Date: January 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-571150/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Umbilical cord mesenchymal stem cells-derived exosomes deliver miR-21 to promote corneal**
2 **epithelial wound healing through PTEN/PI3K/Akt pathway**

3
4 Xiaolong Liu^{1,4#}, Xuran Li^{2,3#}, Guangyuan Wu^{1,3}, Pengfei Qi^{1,3}, Yanyan Zhang², Zhiyu Liu⁵, Xinyue
5 Li², Yu Yu², Xiangmei Ye^{1,3}, Yang Li^{1,3}, Dongguang Yang^{1,3}, Yueqiu Teng^{1,3}, Ce Shi^{1,3}, Xin Jin², Sen
6 Qi⁶, Yuting Liu², Shudan Wang², Ying Liu², Fenglin Cao^{1,3}, Qingran Kong⁴, Zhenkun Wang^{1,3*} and
7 Hong Zhang^{2,3*}

8 ¹ Central Laboratory, First Affiliated Hospital, Harbin Medical University, Harbin, China

9 ² Eye Hospital, First Affiliated Hospital, Harbin Medical University, Harbin, China

10 ³NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin, China

11 ⁴College of Life Science, Northeast Agricultural University, Harbin, China

12 ⁵Department of Laboratory Diagnostics, First Affiliated Hospital, Harbin Medical University,
13 Harbin, China

14 ⁶Department of Hematology, First Affiliated Hospital, Harbin Medical University, Harbin, China

15

16 * Corresponding author.

17 Hong Zhang: zhanghong@hrbmu.edu.cn; Zhenkun wang: wzkc@163.com

18 # These authors contributed equally to this work.

19 **Abstract**

20 **Objective:** Rapid restoration of corneal epithelium integrity after injury is particularly important
21 for preserving corneal transparency and vision. Mesenchymal stem cells (MSCs) can be taken into
22 account as the promising regenerative therapeutics for improvement of wound healing processes

23 based on the variety of the effective components. The extracellular vesicles from MSCs, especially
24 exosomes, has been considered as important paracrine mediators through transferring microRNAs
25 into recipient cell. This study investigated the mechanism of human umbilical cord MSC-derived
26 exosomes (HUMSC-exosomes) on corneal epithelial wound healing.

27 **Methods:** Exosomes extracted from HUMSCs were identified by transmission electron microscopy,
28 nanoparticle tracking analysis, and Western blot. Corneal fluorescein staining and histological
29 staining were evaluated in a corneal mechanical wound model. Changes in HCECs proliferation
30 after HUMSC-exosomes or miR-21 mimics treatment were evaluated by CCK-8 and EdU assays,
31 while migration was assessed by in vitro scratch wound assay. Full-length transcriptome sequencing
32 was performed to identify the differentially expressed genes associated with HUMSC-exosomes
33 treatment, followed by validation via real-time PCR and Western blot.

34 **Results:** The exosomes derived from HUMSCs can significantly promote corneal epithelial cells
35 proliferation, migration in vitro and corneal epithelial wound healing in vivo. Similar effects
36 were obtained after miR-21 transfection, while the beneficial effects of HUMSC-exosomes were
37 partially negated by miR-21 knockdown. Results also show that the benefits are associated with
38 decreased PTEN level and activated the PI3K/Akt signaling pathway in HCECs.

39 **Conclusion:** HUMSC-exosomes could enhance the recovery of corneal epithelial wounds through
40 restraining PTEN by transferring miR-21, and may represent a promising novel therapeutic agent
41 for corneal wound repair.

42
43 **Keywords:** Corneal wound healing; Umbilical cord mesenchymal stem cell; Exosomes; miR-21;
44 PTEN

45

46 **Introduction**

47 Superficial corneal lesions can heal rapidly and without complication, however, delayed corneal
48 epithelial healing can lead to subsequent corneal infections with further complications, such as
49 corneal scarring, thinning, ulceration and even perforation. According to the World Health
50 Organization, it is estimated that corneal opacities, including corneal ulceration, are the fourth
51 leading cause of blindness worldwide [1]. Although several therapies exist and an increasing number
52 of novel approaches are emerging, treatment of severe corneal epithelial defect can still be quite
53 challenging. Therefore, a topical treatment that aids in the management and accelerated closure of
54 corneal wounds would help reduce the risk of infections and scarring, and thus improve visual
55 outcomes.

56

57 Mesenchymal stem cells (MSCs)-based therapies participated in renovating the structure and
58 function of damaged or diseased tissues[2]. However, poor engraftment and limited differentiation
59 of transplanted MSCs suggest that their beneficial effects might not be associated with their
60 differentiation and direct replenishment of damaged tissue parenchymal cells [3, 4]. Currently,
61 emerging evidence has shown that the therapeutic effect of MSCs mainly relies on paracrine
62 activities [5]. MSCs can release extracellular vesicles (EVs) containing bioactive molecules that
63 affect cellular processes in neighboring cells. Therefore, it may be possible to avoid the limitations
64 and complications of stem cell therapy in the eye by using MSC derived EVs as biomimetic agents
65 to accelerate corneal wound healing [6].

66

67 EVs, specifically exosomes, are functional paracrine units of stem cells and have
68 therapeutic effects similar to their parent cells, suggesting that they may provide a promising, cell-
69 free therapeutic options [7-9]. The application of MSC-derived exosomes alone can exert similar
70 functions of MSCs and participate in the regulation of immune response, inflammatory disease and
71 wound healing [10]. The cellular bilayer lipid membrane of exosomes protected proteins, mRNAs,
72 and non-coding RNAs (ncRNAs) from destruction, which can be transferred to recipient cells for
73 cell-to-cell communication [11]. ncRNAs is considered as key post-transcriptional modulators of
74 gene expression and can be transferred in active form via exosomes to regulate the activity of certain
75 cells. Among them, microRNAs (miRNAs) have emerged as the most important modulator [12].
76 miRNAs are a class of evolutionally conserved, single-stranded ncRNAs, which are either
77 transcribed by RNA polymerase II from independent genes or introns of protein-coding genes [13].
78 miRNAs are crucial players during normal development, homeostasis, and disease, which
79 participate in almost every biological process such as cell proliferation and survival [14].

80

81 MSCs from cord tissues are easily attainable and more primitive than MSCs isolated from adult
82 sources. Previous studies have shown that human umbilical cord mesenchymal stem cell derived
83 exosomes (HUMSC-exosomes) could transfer miRNAs and attenuate cell death and enhance
84 cutaneous wound healing [15, 16]. Considering the similar wound healing process between skin and
85 corneal, we studied the functions of HUMSC-exosomes in corneal wound repair. The present study
86 demonstrated the therapeutic effect of HUMSC-exosomes using a corneal mechanical wound model.
87 To investigate the mechanism underlying HUMSC-exosomes-mediated corneal wound repair, we
88 studied the effects of HUMSC-exosomes on human corneal epithelial cells (HCECs) migration and

89 proliferation. Through high-throughput sequencing and bioinformatics analysis, we identified that
90 miR-21 are carried by HUMSC-exosomes as crucial elements contributing to HCECs migration and
91 proliferation by down-regulating PTEN expression.

92

93 **Materials and Methods**

94 **Primary cell culture and Characterization**

95 The umbilical cord was obtained from the Department of Obstetrics and Gynecology of the First
96 Affiliated Hospital of Harbin Medical University after harvesting informed consent for research
97 purposes, which was approved by the Ethics Committee (ethical approval number: 201859). The
98 collected umbilical cord Wharton's jelly tissue was cut into small pieces, and then allowed to stick
99 to the bottom of the cell culture plates. Dulbecco's Modified Eagle's Medium (DMEM) Low
100 Glucose with 10% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin (Gibco, USA)
101 were added to the cells. The dissociated cells were washed with PBS, and stained with antibodies
102 CD90, CD105, CD73, CD34, CD11b, CD19, CD45 and HLA-DR using the BD™ Human MSC
103 Analysis Kit. The FACS analysis was performed using a FACS Calibur™ flow cytometer (BD
104 Biosciences), and the data were analyzed using FlowJo software (BD Biosciences). The release of
105 EVs from HUMSCs was blocked by pre-incubating HUMSCs with 20 μM GW4869 (sigma, USA)
106 for 24 hours. All cells used in our experiments were from early passages 3 to 5.

107

108 To avoid the influence of FBS-derived exosomes on HUMSC-exosomes, HUMSCs used for
109 exosomes extraction were cultured using exosomes-free FBS which were centrifuged at 120,000 g
110 at 4°C for 18 hours using a Beckman Optima L-100 XP ultracentrifuge with a SW 32 Ti rotor.

111

112 **Isolation and identification of HUMSC-exosomes**

113 HUMSCs supernatants was collected at different times every 24-48 hours and centrifuged at 300 g
114 for 10 minutes to pellet dead cells, and cell debris were removed by centrifuging at 2,000 g for 10
115 minutes, and then 10,000 g for 30 minutes to eliminate large vesicles, after centrifuging at 120,000
116 g for 70 minutes, HUMSC-exosomes pellets were washed with PBS and ultracentrifuged at
117 120,000 g for another 70 minutes. All centrifugation steps were performed at 4°C. The purified
118 exosomes were resuspended in PBS and stored at -80 °C.

119

120 The concentration of HUMSC-exosomes was determined by BCA protein assay kit, as suggested
121 by the manufacturer (Beyotime Institute of Biotechnology, China). The morphology of HUMSC-
122 exosomes was observed by transmission electron microscopy (TEM) (JEOL JEM-1220, Japan). And
123 the size distribution of HUMSC-exosomes was measured by nanoparticle tracking analysis (NTA,
124 Malvern Zetasizer, England). The membrane protein marker (CD9, CD81, CD63) were analyzed
125 using Western blot.

126

127 To obtain the miR-21 knockdown HUMSC-exosomes, we transfected MSCs with miR-21 inhibitors
128 (RIBOBIO, China) or negative control (NC) using Opti-MEM (Gibco, USA) and Lipofectamine
129 2000 (Invitrogen) according to the manufacturer's instructions. After 48 hours
130 of culture incubation, exosomes were isolated from culture supernatants by
131 differential centrifugation as described above.

132

133 **HCECs culture and transfection**

134 The human corneal epithelial cell line (HCEC, Bnbio, China) were cultured in DMEM High
135 Glucose supplemented with 10% FBS (Gibco, USA). HCECs were seeded into 6-well or 12-well
136 plates the day before treatment. Prior to HUMSC-exosomes or PBS treatment, HCECs were starved
137 in serum-free DMEM for 24 hours at 50% confluence. HCECs were transfected with miR-21
138 mimics or miR-21 inhibitors and corresponding NC, pCDNA3.1-3×Flag-PTEN and
139 empty vector plasmid as indicated.

140

141 **Exosome uptake assay**

142 For the exosome uptake analysis, 20 μg purified HUMSC-exosomes in 100 μl PBS was incubated
143 with 1 μM Dil (Beyotime Institute of Biotechnology, China) in the dark for 30 min, washed twice
144 with PBS, ultracentrifuged at 120,000 g for 70 min to remove nonbinding dye, and then resuspended
145 in serum-free medium. HCECs were labeled with 5 mM CFSE in the dark for 20 min, washed twice
146 with complete medium. 200 μl cell suspension ($5 \times 10^4/\text{ml}$) was seeded into 35 mm glass bottom
147 dishes (Cellvis, USA) and let the cells adhere to the glass for 12 hours. CFSE-labeled HCECs were
148 co-cultured with Dil-labeled HUMSC-exosomes for 2 hours. After washed with PBS and fixed in
149 4% paraformaldehyde, cell nuclei were stained with DAPI (Beyotime Institute of Biotechnology,
150 China). Images were taken under confocal microscope (Zeiss LSM 710, Germany) and analyzed
151 with supplementary software.

152

153 For TEM observation, HCECs were co-cultured with exosomes (40 $\mu\text{g} / \text{ml}$) for 2 hours and then
154 fixed with 2.5% glutaraldehyde and postfixed with 3% osmium tetroxide (OsO_4) for 2 hours. The

155 specimen was dehydrated in a graded series of ethanol, embedded in Epon resin and then imaged
156 with TEM at 100 kV (Hitachi H-7650, Japan).

157

158 **In vitro Wound healing assay**

159 HCECs were seeded into six-well plates and grown to confluence. The monolayer was scratched
160 using a 200 μ l pipette tip and washed with serum-free medium to remove detached cells. Then, the
161 cells were kept in co-culture with HUMSC-exosomes or not. At different times, images of wound
162 scratch were taken under a microscope. The scratch closure was analyzed by ImageJ software. The
163 percentage of wound closure was calculated as follows: migration area (%) = $(A_0 - A_n)/A_0 \times 100$,
164 where A_0 represents the initial wound area, and A_n represents the wound area at the time of
165 measurement.

166

167 **In vitro Cell proliferation assay**

168 HCECs proliferation was measured using the cell counting kit-8 (CCK-8, Sigma, USA) according
169 to the manufacturer's protocol. The optical density (OD) at 450 nm was measured with averages
170 from three replicates using a microplate reader (BioTek Instruments, USA).

171

172 **In vitro EdU proliferation assay**

173 Cell proliferation was also assessed using EdU Cell Proliferation Assay kit (RiboBio, China)
174 according to the manufacturer's protocol. Briefly, after treatment, HCECs were exposed to 50 μ M
175 5-ethynyl-2'-deoxyuridine (EdU, RiboBio) for 2 h at 37°C, and then the cells were fixed in 4%
176 paraformaldehyde. After permeabilization with 0.5% Triton-X100, the cells were reacted with 1 \times

177 Apollo reaction cocktail for 30 minutes. Subsequently, the DNA contents of the cells were stained
178 with Hoechst33342 for 30 minutes. Finally, the proportion of the cells incorporating EdU was
179 determined with fluorescence microscopy (OLYMPUS, IX51).

180

181 **Western blot**

182 HUMSC-exosomes and HCECs were lysed in lysis buffer containing protease and phosphatase
183 inhibitor (Beyotime Institute of Biotechnology, China). Proteins was separated by electrophoresis
184 after loading onto polyacrylamide gel, and then transferred to the PVDF that was incubated with
185 primary antibodies against phospho-Akt (4060s, CST), PTEN (9188, CST), CD9 (ab92726, Abcam),
186 CD61 (ab59479, Abcam), CD81 (00679767, Invitrogen) overnight at 4°C after blocking with 5%
187 nonfat milk, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary
188 antibody. Proteins were detected with a Western blot analysis system.

189

190 **PCR**

191 Total RNA of cells was extracted using TRIzol kit (Invitrogen, USA). RT-qPCR was carried out
192 using the SYBR® Premix Ex Taq™ kit (Takara Bio, Japan) according to the manufacturer's
193 instructions. The thermocycling conditions (Bio-Rad, CFX96) used were as follows: 95°C for 3
194 minutes; followed by 40 cycles of 95°C for 5 seconds, 60°C for 30 seconds and 72°C for 30 seconds,
195 followed by a final extension of 72°C for 5 minutes. Relative expression of these genes was
196 calculated by the $2^{-\Delta\Delta C_t}$ method.

197

198 **Bioinformatics analysis**

199 HUMSC-exosomes microRNA expression microarray GSE69909 were downloaded from GEO
200 database. Target Scan, mirBase and miRDB were used to predict the target genes of miRNAs
201 enriched in exosomes. All the predicted targets have target prediction scores ≥ 80 were subjected to
202 gene ontology (GO) analysis to investigate the underlying mechanism of the potential HUMSC-
203 exosomes miRNA and the target mRNAs during corneal re-epithelialization.

204

205 **Full-length transcriptome sequencing**

206 HCECs (2.5×10^6 cells) were treated with $40\mu\text{g/ml}$ HUMSC- exosomes for 48 hours, same volume
207 of PBS was added as control with three biological replicates. Total RNA was isolated
208 using the TRIzol reagent according to the manufacturer's instructions. $1\mu\text{g}$ total RNA was prepared
209 for cDNA libraries using cDNA-PCR Sequencing Kit (SQK-PCS109) protocol provided by Oxford
210 Nanopore Technologies (ONT). Briefly, the template switching activity of reverse transcriptase
211 enrich for full-length cDNAs and add defined PCR adapters directly to both ends of the first-strand
212 cDNA. And following cDNA PCR for 14 circles with LongAmp Tag (NEB). The PCR products
213 were then subjected to ONT adaptor ligation using T4 DNA ligase (NEB). Agencourt XP beads was
214 used for DNA purification according to ONT protocol. The final cDNA libraries were added to FLO-
215 MIN109 flowcells and run on PromethION platform at Biomarker Technology Company (Beijing,
216 China). KOBAS software was used to test the statistical enrichment of differential expression
217 transcripts in KEGG pathways.

218

219 **Corneal mechanical wound model and treatment**

220 The experimental protocols were approved by The Ethics Committee of First Affiliated Hospital of

221 Harbin Medical University (ethical approval number: 2020100). Weight from 160–180g male
222 Sprague-Dawley rats (6-8 weeks old) were purchased from the animal experiment center of the
223 Second Affiliated Hospital of Harbin Medical University. The rats were anesthetized with
224 intraperitoneal injection and applied topically 0.5% proparacaine, the corneal epithelium was
225 removed up to the corneal/limbal border with AlgerBrush II (The Alger Company, Lago Vista, TX,
226 USA) as previously described [17]. A unilateral corneal injury was created. Protocols were approved
227 by the Harbin Medical University Animal Care and Use Committee guideline.

228

229 Rats were randomly divided into four groups and subconjunctival injected with 100 μ l PBS
230 containing 2×10^6 HUMSCs, equal amount of HUMSCs pretreated with GW4869, 40 μ g HUMSC-
231 exosomes or an equal volume of PBS, respectively. Wound residual area was monitored every 12
232 hours using fluorescein staining and photographed using a camera equipped Nikon FS-2 slit lamp
233 biomicroscope. The percentages of residual defect were analyzed by ImageJ software.

234

235 **Histological analysis**

236 The eyes were enucleated and post-fixed with 4% paraformaldehyde within 10 minutes after
237 euthanasia. 4 μ m paraffin-embedded sections stained with hematoxylin and eosin (H&E) were used
238 to observe the corneal structure and degree of corneal re-epithelialization. The sections were
239 photographed under light microscope (Olympus, Japan).

240

241 **Statistical analysis**

242 All statistical analyses were performed using Prism software. Data are summarized as mean \pm

243 standard deviation (SD). Student *t*-test was used to determine statistically significant differences
244 between samples. When multiple comparison analyses were required, statistical significance was
245 evaluated by one-way ANOVA. All *P*-values <0.05 were considered statistically significant.

246


247 **Results**

248 **1. Identification of HUMSCs and HUMSC-exosomes**

249 Results of flow cytometry analysis confirmed the presence of positive expressions of typical MSC
250 makers CD105, CD90, CD73, while the surface markers of hematopoietic cells such as CD34,
251 CD11b, CD19, CD45 and HLA-DR were fairly weak to detect compared with the isotype control
252 (Fig. 1(a)). In addition, according to inverted microscopic observation, the morphology of the cells
253 was regular long spindle with directional arrangement, and presented a typical spindle shape, which
254 grew as whirlpool or cluster (Fig. 1(b)).

255

256 The classical structure of the isolated exosome, including “rim of a cup” and double-layer membrane
257 morphology, were observed by TEM (Fig. 1(c)). NTA results demonstrated that the diameters of the
258 particles were around 50–150 nm (Fig. 1(d)). The identity of these particles was further confirmed
259 as exosomes by Western blot, which showed the presence of widely expressed exosomal markers,
260 including CD9, CD63, CD81 (Fig. 1(e)). Therefore, results above confirmed that the EVs we
261 extracted were indeed exosomes.



262

263 Figure. 1

264 Morphological observation and identification of HUMSCs and HUMSC-exosomes. (a) Flow cytometry analysis of

265 surface markers in HUMSCs. (b) Light morphology image of HUMSCs. (c) Morphology of HUMSC-exosomes

266 under TEM. Scale bar, 100 nm. (d) Peak size of HUMSC-exosomes was around 80 nm as showed by NTA. (e)

267 HUMSC-exosomes were positive for CD9, CD81 and CD63 as indicated by Western blot.


268

269 **2. Application of HUMSCs or HUMSC-exosomes promotes corneal wound healing in a rat**
 270 **model**

271 We found that subconjunctival injection of HUMSCs or HUMSC-exosomes can effectively promote

272 the healing of corneal defects in rats, while inhibition of exosome secretion by GW4869 can

273 attenuated HUMSCs mediated benefits at 24 hours (Fig. 2(a) and (c)). The injured corneas
274 treated with HUMSC and HUMSC-exosomes regained more regular arrangement and
275 compact structure than those treated with PBS through assessing corneal tissues microstructure by
276 H&E staining (Fig. 2(b)).



277

278 Figure. 2

279 The effect of HUMSCs and HUMSC-exosomes on corneal epithelial wound healing in vivo. (a, c) Fluorescein-


280 stained images of defect corneas, before and after treatment with HUMSCs, HUMSCs-GW4869, HUMSC-exosomes
281 or PBS. (b) H&E staining showed the histologic appearance of the cornea. Data are expressed as the means \pm SD.
282 * P < 0.05, ** P < 0.01, and *** P < 0.001, n = 8.

283

284 **3. HUMSC-exosomes promote the proliferation and migration of HCECs in vitro**

285 To demonstrate the uptake of exosomes, CFSE-labelled HCECs were co-cultured with Dil-labelled
286 exosomes and then visualized with laser scanning confocal microscope. The red nanoparticles
287 represent the labeled exosomes that occurred in smaller clusters and were observed either
288 surrounding the cell membrane or within the cytoplasm in HCECs. Localization results showed that
289 exosomes derived from HUMSCs had been taken up by HCECs with the dye distributing within in
290 the cell (Fig. 3(a)). In addition, the fusion process was also observed by TEM (Fig. 3(b)).

291 In order to evaluate whether HUMSC-exosomes stimulates HCECs migration, the effect on wound
292 closure rates were investigated. The disparity of the remaining area during scratch wound assays
293 confirmed the promigratory effects of HUMSC-exosomes with a dose-related trend after 18 hours
294 incubation (Fig. 3(c) and (d)). Considering corneal healing is a dynamic interwoven process
295 composed of cell proliferation, migration and adhesion, and the proliferation ability is the basis. We
296 further investigated whether HUMSC-exosomes could enhance the proliferation-promoting
297 behavior of HCECs in vitro. The CCK-8 assay showed that the proliferation of HCECs after
298 incubating with exosomes was significantly improved in a dose-dependent manner (Fig. 3(e)). And
299 the EdU assays for visualization of proliferating cells also demonstrated that HUMSC-exosomes
300 treatment increased the percentage of proliferating cells compared to controls (Fig. 3(f) and (g)).



301

302 Figure. 3

303 The effect of HUMSC-exosomes on HCECs proliferation and migration in vitro. (a) Fluorescence images

304 of CFSE-labelled HCECs (green) incubated with Dil-labelled HUMSC-exosomes (red). Nuclei were stained with

305 DAPI (blue). (b) TEM of HCECs incubated with HUMSC-exosomes. (c, d) Representative images from in vitro

306 scratch wound healing assays demonstrating that cell migrate into the cell-free region is significantly promoted in

307 the presence of HUMSC-exosomes when compared to controls, $n = 4$. (e) CCK-8 assay showed increased
308 proliferation of HCECs incubated with HUMSC-exosomes after 48 hours, $n = 5$. (f, g) The proliferating HCECs
309 was detected by EdU incorporation. The cells were treated with HUMSC-exosomes or blank control, $n = 3$. Blue:
310 nuclear staining (Hoechst33342); Red: EdU staining. Data are expressed as the means \pm SD. $*P < 0.05$,
311 $**P < 0.01$, and $***P < 0.001$.


312

313 **4. HUMSC-exosomes promote HCECs proliferation and migration through PI3K/Akt pathway**


314 To further investigate the potential mechanism of HUMSC-exosomes regulated proliferation and
315 migration in HCECs, full-length transcriptome sequencing was used to detect the mRNA
316 expression levels of related genes. 240 differentially expressed genes (DEG) were identified (Fold
317 Change ≥ 2 and P value < 0.05), including 104 up-regulated DEGs and 136 down-regulated DEGs
318 (Fig. 4(a)). Then, we interpreted the potential biological functions of DEGs from the gene function
319 and signaling pathway through KEGG enrichment analysis, and revealed that the PI3K/Akt
320 signaling pathway, the phosphatidylinositol signaling system, cell adhesion molecules and MAPK
321 signaling pathway had a significant difference between before and after HUMSC-exosome
322 treated HCECs (Fig. 4(b)). Previous studies demonstrated that PI3K/Akt pathway involved deeply
323 in the modulation of the process of corneal epithelial wound healing [18]. Therefore, the PI3K/Akt
324 signaling pathways involved in HCECs proliferation and migration process after HUMSC-
325 exosomes treatment were explored.

326

A



B



327

328 Figure. 4

329 Transcriptome and pathway analysis of HUMSC-exosomes treatment. (a) Volcano Plot of DEGs between HUMSC-

330 exosomes treated and untreated HCECs. Dots in green stands for down-regulated DEGs and red dots mean up-

331 regulated DEGs, black dots are non-significant DEGs. (b) The KEGG annotation results of the DEGs were classified

332 according to the pathway types in KEGG. DEG, differentially expressed genes; KEGG, Kyoto Encyclopedia of

333 Genes and Genomes

334


335 5. Exosomal miR-21 regulates the PTEN/ PI3K/AKT signaling pathway

336 Exosomes regulate a large number of physiological activities via exosomal miRNAs [20]. As

337 miRNAs are abundant in HUMSC-derived exosomes, we hypothesized that HUMSC-exosomes

338 promote the healing of corneal epithelial defect mainly through miRNAs. The downloaded dataset

339 was used to determine the content of various miRNAs in HUMSC-exosomes [21]. Among the
 340 several miRNAs selectively enriched in HUMSC-exosomes, we focused on the most abundant one,
 341 miR-21(Fig. 5(a)). The downstream targets were predicted by Target Scan, mirBase and miRDB
 342 database, then imputed DAVID online to conduct GO analysis. The results showed that miR-21 was
 343 involved in the regulation of various molecular function, containing calcium ion binding, peptidase
 344 inhibitor activity, growth factor activity etc. (Fig. 5(b)). Among them, the phosphatase activity may
 345 involve in the regulation of PI3K/Akt. miRNAs can exert their functions by interacting with the 3'
 346 untranslated region (3' UTR) or protein coding sequence of target mRNAs. According to the
 347 miRbase database, PTEN might be the potential downstream of miR-21 (Fig. 5(c)).




348
 349 Figure. 5

350 Identification of HUMSC-exosomal microRNAs. (a) miRNAs abundance analysis of HUMSC-exosomes. (b)
 351 mRNA targets for the microRNAs significantly enriched in HUMSC-exosomes were identified and GO analysis. (c)
 352 The binding site between miR-21 and PTEN mRNA. MF, molecular function; GO, Gene Ontology

353

354 Unsurprisingly, we found that reduced mRNA and protein expression levels of PTEN were
 355 identified within HCECs after treated with HUMSC-exosomes (Fig. 6(a) and (d)). The activation of

356 the PI3K/Akt pathway in HCECs following HUMSC-exosome stimulation was verified by
357 assessing the phosphorylated Akt levels (Fig. 6(d)). To confirm whether PTEN is a target of miR-
358 21 in HCECs, we further measured the expression of PTEN in HCECs transfected independently
359 with miR-21 mimics or inhibitors and their corresponding NC to verify the interaction between the
360 miR-21 and PTEN by qRT-PCR and Western blot. Once transfected with miR-21 mimics, the
361 protein levels of PTEN were significantly reduced in HCECs (Fig. 6(f)), and the difference was also
362 detected in transcription level (Fig. 6(b) and (c)). We also found that the effects of miR-21 on the
363 Akt phosphorylation were stimulative (Fig. 6(g)). Meanwhile, overexpression of PTEN down-
364 regulated the phosphorylated Akt levels, which was important for proliferation and migration (Fig.
365 6(e)). These results suggested that miR-21 regulate PTEN within HCECs via post-transcriptional
366 modify.



367

368 Figure. 6

369 Exosomal miR-21 regulate HCECs proliferation and migration by activating PI3K/Akt pathway through

370 targeting PTEN. (a, d) HUMSC-exosomes treatment decreased the RNA and protein levels of PTEN in HCECs. (b)

371 The expression level of miR-21 in HCECs. (c, f) The PTEN changed with miR-21 variation. (e) The expression of

372 phospho-Akt after overexpression of PTEN. (g) The expression level of phospho-Akt after transfected with miR-21

373 mimics was detected by Western blot. Data are expressed as the means \pm SD. * $P < 0.05$, ** $P < 0.01$, and

374 *** $P < 0.001$.

375

376 6. HUMSC-exosomes promote HCECs proliferation and migration through miR-21


377 In order to assess whether the exosome-mediated miR-21 transfer plays a role in HCECs

378 proliferation and migration, a subsequent knockdown experiment was conducted. HUMSCs were
379 transfected with miR-21 inhibitors (at final concentration of 100 nM) or NC, and the culture
380 supernatants were collected subsequently for isolating the exosomes. Then, HCECs were incubated
381 with the same concentration of miR-21 contained or miR-21 knockdown HUMSC-exosomes for
382 migration and CCK-8 analysis. Results showed that the up-regulation of migration (Fig. 7(a) and
383 (b)), as well as proliferation (Fig. 7(c)) induced by HUMSC-exosomes were partially negated by
384 miR-21 knockdown.

385

386 To further study the potential involvement of miR-21, HCECs were transiently transfected with
387 miR-21 mimics or NC. Proliferation of HCECs following transfection with miR-21 mimics or NC
388 was assessed using CCK-8 and EdU assay. miR-21 mimics transfection significantly promoted
389 the proliferation of HCECs compared with the NC group (Fig. 7(d)-(f)). In addition, the ability of
390 HCECs transfected with miR-21 mimics to regain monolayer integrity was raise compared with
391 NC-transfected cells (Fig. 7(g) and (h)).

392 Taken together, our data indicate that exosomal miR-21 promotes proliferation and migration by
393 activating PI3K/Akt signaling pathway, which might play a critical role to enhance corneal epithelial
394 wound healing.



395


396 Figure. 7

397 miR-21 involved in the process of HUMSC-exosomes promote cell proliferation and migration. (a, b) HCECs were

398 treated with miR-21KD HUMSC-exosomes or miR-21 contained HUMSC-exosomes for 18h. The scratch assay

399 showed the healing of the miR-21KD HUMSC-exosomes treated group was slower than the miR-21 contained
 400 HUMSC-exosomes treated group, $n = 5$. (c) The CCK-8 assay showed the proliferation of the miR-21 KD HUMSC-
 401 exosomes treated group was lower than the miR-21 contained HUMSC-exosomes treated group after 18 hours, $n = 3$.
 402 (d, e) The proliferation of HCECs was detected by EdU incorporation after transfected with miR-21 mimics (at final
 403 concentration of 50 nM). Blue: nuclear staining (Hoechst33342); Red: EdU staining, $n = 3$. (f) The CCK-8 assay
 404 showed the proliferation of the miR-21 mimics group was higher than control group after 48 hours, $n = 3$. (g, h) The
 405 scratch assay showed significantly faster wound closure in HCECs incubated with miR-21 mimics than NC after 18
 406 hours, $n = 5$. Data are expressed as the means \pm SD. $*P < 0.05$, $**P < 0.01$, and $***P < 0.001$. KD, knockdown

407 **7. Schematic diagram**



408

409 Figure. 8

410 Schematic diagram describes the mechanism of HUMSC-exosomes in corneal epithelial defect.

411

412 We first determined the positive effects of exosomes derived from HUMSCs in promoting corneal
413 epithelial wound healing, then determined the main molecules PI3K/Akt in the wound healing
414 process and the fact that miR-21 was the most abundantly contained in exosomes through
415 bioinformatics analysis. Finally, we anchored PTEN as the downstream target of miR-21, which
416 was the key link between miR-21 and related protein, and determined that PTEN/PI3K/Akt were
417 involved in cell proliferation and migration.

418

419 **DISCUSSION**

420 Corneal epithelial damage is one of the most common ocular disorders, and novel treatments are
421 needed to improve clinical outcomes for this type of disease. The current study demonstrated the
422 beneficial effect of HUMSC-exosomes on corneal injury. To elucidate the potential mechanism
423 associated with this activity, our in vitro results revealed that HUMSC-exosomes promotes HCECs
424 proliferation and migration via repression of PTEN expression and downstream effects involving
425 the phosphorylation of Akt. Moreover, exosomal miR-21 as an important regulator also showed the
426 effect in promoting HCECs proliferation and migration by targeting PTEN. Our results suggested
427 that HUMSC-exosomes may be an exceptionally meaningful and promising approach for the
428 healing of corneal defects.

429 As a cell-based therapy for treating human diseases has gained increasing interest over the last few
430 decades, hundreds of clinics or clinical trials using human MSCs have carried out, and showed that
431 the application of MSCs can enhance wound healing[22] and ameliorate fibrosis[23]. In this study,
432 we have shown that subconjunctival injection of HUMSCs facilitated corneal epithelial
433 wound healing. However, several recent studies suggest that the therapeutic effects of MSCs may

434 be largely mediated by paracrine effects involving proteins/peptides, hormones and vesicles
435 packaging various molecules[24]. Among such effectors, exosomes are considered to be the key
436 effectors to exert therapeutic function. In order to further confirm if HUMSCs paracrine effects
437 dominate the process of cornea wound healing, HUMSCs were pretreated with GW4869, a
438 exosomes generation blocker[25]. Expectedly, HUMSCs were less effective in enhancing wound
439 healing when the release of exosomes was blocked. These results implicating the function of
440 HUMSCs particularly rely on exosomes release into the microenvironment.

441

442 Researches have shown that independent application of MSC-exosomes can also play a critical role
443 in promoting the repair of damaged tissues [26]. Moreover, MSC-exosomes have many advantages
444 over MSCs, such as less safety concerns [27], long-term preservation and easy transportation [28],
445 lower immunogenicity [29], capacity to cross biological barriers [30]. Previous studies have shown
446 that exosomes from corneal MSCs can reduce scar formation and increase the transparency of
447 corneal healing [31]. Exosomes from placental MSCs can reduce the inflammatory response during
448 corneal alkali burn and promote the restoration of normal corneal structure [32]. Exosomes from
449 bone marrow MSCs promoted survival of retinal ganglion cells and regeneration of their axons
450 through miRNA-dependent mechanisms[33]. In present study, for the first time, we proved that
451 HUMSC-exosomes could promote the repair of corneal epithelium integrity and the healing process
452 of corneal injury both in vitro and in vivo.

453

454 Since miRNAs was first identified by Lee RC, new miRNAs are still being discovered with the
455 development of high-throughput sequencing technologies and computational and bioinformatics

456 prediction methods [34]. Increasing evidences indicated that exosomal miRNAs can prevent target
457 mRNA from translating into protein as posttranscriptional regulation [21]. In most cases, miRNAs
458 interact with the 3' UTR of target mRNAs in a complementary manner to suppress protein
459 translation and then regulate cell proliferation, differentiation, development and senescence [35, 36].
460 Acting as the crucial mediators of MSC-exosomes, miRNAs can provide sustained therapeutic
461 effect and fundamental alterations of the local microenvironment, making it an ideal therapeutic
462 biomolecule [37]. Many studies have validated the role of miRNAs in exosomes in various types of
463 cells [38, 39]. In order to further explore how HUMSC-exosomes affects the corneal epithelial cells,
464 we consulted GEO dataset and combined with bioinformatic analysis methods to analyze the content
465 composition of exosomal miRNAs, and transcriptome sequencing was performed to identify the
466 DEGs in HUMSC-exosomes treated HCECs compared to untreated condition. We found that
467 exosomes derived from HUMSCs were rich in miR-21, which might act as the physiological and
468 pathological regulatory factor. In our study, the exosomes extracted from miR-21 KD HUMSCs
469 weaken the effect on HCECs proliferation and migration compared with those extracted form miR-
470 21 contained HUMSCs, implicating the function of HUMSC-exosomes partly depends on miR-21.
471 miR-21 overexpression has the similar effect on promoting proliferation and migration of corneal
472 epithelial cells. These results showed that miR-21 has a fundamental function on corneal epithelial
473 cell amplification. miR-21 is a proliferation-related miRNA, and its role in wound healing was
474 demonstrated in skin wound models [40] and cornea wound healing [41]. Despite previews results
475 proved miR-21/SPRY2 axis participated in modulating epithelial phenotypes, promoted the
476 migration of corneal epithelial cells and enhance the wound healing process, the mechanisms
477 underlying miR-21 effect on corneal epithelial wound healing remain largely unknown.

478

479 PI3K/Akt pathway is a signal transduction pathway closely related to cell growth and proliferation,
480 and plays an important mediating role in proliferation, differentiation and apoptosis of normal cells.
481 The signal protein activity was increased in the tissue cells with strong proliferation ability
482 [42]. Studies have shown that the activation of PI3K and Akt can trigger and accelerate the
483 transformation and proliferation of skin epithelial cells, while the use of inhibitors can inhibit the
484 proliferation of cancer cells and improve the level of programmed cell death [43, 44]. Once the
485 PI3K/Akt Signaling pathway was suppressed, corneal epithelial migration was delayed [45-47].
486 These observations from various experiments suggest that PI3K/Akt signaling may have the
487 stimulatory effect in the maintenance of the corneal epithelium integrity. In our experiment,
488 PI3K/Akt pathways were activated in HCECs proliferation and migration promoted by HUMSC-
489 exosomes. miR-21 could weaken the expression level of PTEN, and increase PI3K/Akt signaling
490 activation in HCECs.

491

492 The downstream of miR-21 has been verified based on the starBase database prediction, dual-
493 luciferase reporter gene assay and evidences from other researches [48-50]. PTEN was the potential
494 effector, which belongs to tumor suppressor gene and inhibits the phosphorylation level of key
495 proteins in various signaling pathways to play a negative function by promoting cell apoptosis and
496 cell cycle arrest, and regulating cell migration and other links [51]. Recent studies have shown that
497 PTEN is involved in the pathological mechanism of myocardial injury and neurocognition, also in
498 regulating corneal epithelial defects [47, 52-54]. In addition, PTEN remains the main negative
499 regulator of PI3K/Akt signaling through its phosphoinositide phosphatase activity [55].

500 To confirm the relationship among miR-21, PTEN and PI3K/Akt, we transferred miR-21mimics
501 into HCECs, and found that miR-21 overexpression could down-regulate the expression level of
502 PTEN, and this down-regulation further induced the up-regulation of phospho-Akt. These results
503 demonstrated that miR-21 promoted HCECs proliferation and migration by regulating PI3K/Akt
504 via PTEN.

505

506 Exosomes are nano-sized vesicles which could be delivered using a needle as small as possible, and
507 their biological activity would not be affected by the increased inner pressure of the needle. We
508 proposed that HUMSC-exosomes can not only be used as a local drug to promote corneal epithelial
509 defects, but also can be injected for more intraocular diseases that cannot be treated locally, thus
510 serving as a putative therapeutic agent. Although we substantiated that miR-21 in HUMSC derived-
511 exosomes mediated the effect of proliferation and migration in HCECs, there still remains unclear
512 whether other exosomal cargoes (protein, DNA, liquid) function as similar roles awaits further
513 investigations. In addition, as the situation of patient with severe corneal epithelial defect is much
514 more complex than that in animal models, whether HUMSC-exosomes can promote the healing of
515 severe corneal injury in clinical practice remains unknown. However, our study proved that the
516 administration of HUMSC-exosomes eye drops is a promising strategy for the treatment of corneal
517 epithelial defect, which serves as a foundation for the development of more effective strategy in
518 corneal wound healing.

519

520 **Conclusions**

521 In conclusion, this study firstly revealed the function of HUMSC-exosomes in promoting corneal

522 epithelial cell proliferation and migration via up-regulating the PI3K/Akt signaling pathway though
523 restraining PTEN by transferring miR-21, leading to better corneal wound repair and regeneration.
524 Our results offer a novel therapeutic agent for the treatment of a corneal wound as a cell-free therapy.

525

526 **Data Availability**

527 The data that support the findings of this study are available from the corresponding author upon
528 reasonable request.

529

530 **Conflicts of Interest**

531 The authors declare no conflict of interest regarding the publication of this paper.

532

533 **Acknowledgments**

534 This work was supported by the National Natural Science Foundation of China (Grant No.
535 U20A20363, 81970776, 8210061916), the Natural Science Foundation of Heilongjiang Province,
536 China (Grant No. LH2020H039).

537

538 **Authors' Contributions**

539 Xiaolong Liu and Xuran Li contributed equally to this work.

540

541 **References**

- 542 1. Resnikoff, S., D. Pascolini, D. Etya'ale, I. Kocur, R. Pararajasegaram, G.P. Pokharel, and S.P.
543 Mariotti, *Global data on visual impairment in the year 2002*. Bull World Health Organ, 2004.
544 **82**(11): p. 844-51.
- 545 2. Kimbrel, E.A. and R. Lanza, *Next-generation stem cells - ushering in a new era of cell-based*

- 546 *therapies*. Nature reviews. Drug discovery, 2020. **19**(7): p. 463-479.
- 547 3. Mathew, B., S. Ravindran, X. Liu, L. Torres, M. Chennakesavalu, C.-C. Huang, L. Feng, R. Zelka, J.
548 Lopez, M. Sharma, and S. Roth, *Mesenchymal stem cell-derived extracellular vesicles and*
549 *retinal ischemia-reperfusion*. Biomaterials, 2019. **197**: p. 146-160.
- 550 4. Toma, C., W.R. Wagner, S. Bowry, A. Schwartz, and F. Villanueva, *Fate of culture-expanded*
551 *mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics*. Circ Res,
552 2009. **104**(3): p. 398-402.
- 553 5. Fan, X.-L., Y. Zhang, X. Li, and Q.-L. Fu, *Mechanisms underlying the protective effects of*
554 *mesenchymal stem cell-based therapy*. Cellular and molecular life sciences : CMLS, 2020. **77**(14):
555 p. 2771-2794.
- 556 6. Heldring, N., I. Mäger, M.J. Wood, K. Le Blanc, and S.E. Andaloussi, *Therapeutic Potential of*
557 *Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles*. Hum Gene Ther, 2015.
558 **26**(8): p. 506-17.
- 559 7. An, Y., S. Lin, X. Tan, S. Zhu, F. Nie, Y. Zhen, L. Gu, C. Zhang, B. Wang, W. Wei, D. Li, and J. Wu,
560 *Exosomes from adipose-derived stem cells and application to skin wound healing*. Cell
561 proliferation, 2021. **54**(3): p. e12993.
- 562 8. Tang, Y., Y. Zhou, and H.-J. Li, *Advances in mesenchymal stem cell exosomes: a review*. Stem cell
563 research & therapy, 2021. **12**(1): p. 71.
- 564 9. Qiao, L., S. Hu, S. Liu, H. Zhang, H. Ma, K. Huang, Z. Li, T. Su, A. Vandergriff, J. Tang, T. Allen, P.-
565 U. Dinh, J. Cores, Q. Yin, Y. Li, and K. Cheng, *microRNA-21-5p dysregulation in exosomes derived*
566 *from heart failure patients impairs regenerative potential*. The Journal of clinical investigation,
567 2019. **129**(6): p. 2237-2250.
- 568 10. Sun, Y., H. Shi, S. Yin, C. Ji, X. Zhang, B. Zhang, P. Wu, Y. Shi, F. Mao, Y. Yan, W. Xu, and H. Qian,
569 *Human Mesenchymal Stem Cell Derived Exosomes Alleviate Type 2 Diabetes Mellitus by*
570 *Reversing Peripheral Insulin Resistance and Relieving beta-Cell Destruction*. ACS Nano, 2018.
571 **12**(8): p. 7613-7628.
- 572 11. Marote, A., F.G. Teixeira, B. Mendes-Pinheiro, and A.J. Salgado, *MSCs-Derived Exosomes: Cell-*
573 *Secreted Nanovesicles with Regenerative Potential*. Front Pharmacol, 2016. **7**: p. 231.
- 574 12. Lopez-Verrilli, M.A., A. Caviedes, A. Cabrera, S. Sandoval, U. Wyneken, and M. Khoury,
575 *Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic*
576 *outgrowth*. Neuroscience, 2016. **320**: p. 129-39.
- 577 13. Krol, J., I. Loedige, and W. Filipowicz, *The widespread regulation of microRNA biogenesis,*
578 *function and decay*. Nat Rev Genet, 2010. **11**(9): p. 597-610.
- 579 14. Dong, H., J. Lei, L. Ding, Y. Wen, H. Ju, and X. Zhang, *MicroRNA: function, detection, and*
580 *bioanalysis*. Chem Rev, 2013. **113**(8): p. 6207-33.
- 581 15. Zhao, G., F. Liu, Z. Liu, K. Zuo, B. Wang, Y. Zhang, X. Han, A. Lian, Y. Wang, M. Liu, F. Zou, P. Li, X.
582 Liu, M. Jin, and J.Y. Liu, *MSC-derived exosomes attenuate cell death through suppressing AIF*
583 *nucleus translocation and enhance cutaneous wound healing*. Stem cell research & therapy,
584 2020. **11**(1): p. 174.
- 585 16. Fang, S., C. Xu, Y. Zhang, C. Xue, C. Yang, H. Bi, X. Qian, M. Wu, K. Ji, Y. Zhao, Y. Wang, H. Liu, and
586 X. Xing, *Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress*
587 *Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor- β /SMAD2 Pathway*
588 *During Wound Healing*. Stem cells translational medicine, 2016. **5**(10): p. 1425-1439.
- 589 17. Di, G., X. Du, X. Qi, X. Zhao, H. Duan, S. Li, L. Xie, and Q. Zhou, *Mesenchymal Stem Cells Promote*

- 590 *Diabetic Corneal Epithelial Wound Healing Through TSG-6-Dependent Stem Cell Activation and*
591 *Macrophage Switch*. Investigative ophthalmology & visual science, 2017. **58**(10): p. 4344–4354.
- 592 18. Cao, L., E.O. Graue-Hernandez, V. Tran, B. Reid, J. Pu, M.J. Mannis, and M. Zhao,
593 *Downregulation of PTEN at corneal wound sites accelerates wound healing through increased*
594 *cell migration*. Investigative ophthalmology & visual science, 2011. **52**(5): p. 2272-2278.
- 595 19. Chang, F., J.T. Lee, P.M. Navolanic, L.S. Steelman, J.G. Shelton, W.L. Blalock, R.A. Franklin, and
596 J.A. McCubrey, *Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and*
597 *neoplastic transformation: a target for cancer chemotherapy*. Leukemia, 2003. **17**(3): p. 590-
598 603.
- 599 20. Pan, Y., X. Hui, R.L.C. Hoo, D. Ye, C.Y.C. Chan, T. Feng, Y. Wang, K.S.L. Lam, and A. Xu, *Adipocyte-*
600 *secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-*
601 *induced adipose inflammation*. J Clin Invest, 2019. **129**(2): p. 834-849.
- 602 21. Zhu, Z., Y. Zhang, Y. Zhang, H. Zhang, W. Liu, N. Zhang, X. Zhang, G. Zhou, L. Wu, K. Hua, and J.
603 Ding, *Exosomes derived from human umbilical cord mesenchymal stem cells accelerate growth*
604 *of VK2 vaginal epithelial cells through MicroRNAs in vitro*. Hum Reprod, 2019. **34**(2): p. 248-
605 260.
- 606 22. Liu, W., M. Yu, D. Xie, L. Wang, C. Ye, Q. Zhu, F. Liu, and L. Yang, *Melatonin-stimulated MSC-*
607 *derived exosomes improve diabetic wound healing through regulating macrophage M1 and*
608 *M2 polarization by targeting the PTEN/AKT pathway*. Stem Cell Res Ther, 2020. **11**(1): p. 259.
- 609 23. Yin, F., W.Y. Wang, and W.H. Jiang, *Human umbilical cord mesenchymal stem cells ameliorate*
610 *liver fibrosis in vitro and in vivo: From biological characteristics to therapeutic mechanisms*.
611 World J Stem Cells, 2019. **11**(8): p. 548-564.
- 612 24. Xunian, Z. and R. Kalluri, *Biology and therapeutic potential of mesenchymal stem cell-derived*
613 *exosomes*. Cancer Sci, 2020. **111**(9): p. 3100-3110.
- 614 25. Zhang, Y.Z., F. Liu, C.G. Song, X.L. Cao, Y.F. Zhang, H.N. Wu, C.J. Guo, Y.Q. Li, Q.J. Zheng, M.H.
615 Zheng, and H. Han, *Exosomes derived from human umbilical vein endothelial cells promote*
616 *neural stem cell expansion while maintain their stemness in culture*. Biochem Biophys Res
617 Commun, 2018. **495**(1): p. 892-898.
- 618 26. Phinney, D.G. and M.F. Pittenger, *Concise Review: MSC-Derived Exosomes for Cell-Free Therapy*.
619 Stem Cells, 2017. **35**(4): p. 851-858.
- 620 27. Tatsumi, K., K. Ohashi, Y. Matsubara, A. Kohori, T. Ohno, H. Kakidachi, A. Horii, K. Kanegae, R.
621 Utoh, T. Iwata, and T. Okano, *Tissue factor triggers procoagulation in transplanted*
622 *mesenchymal stem cells leading to thromboembolism*. Biochemical and biophysical research
623 communications, 2013. **431**(2): p. 203-209.
- 624 28. Kim, H.J. and J.S. Park, *Usage of Human Mesenchymal Stem Cells in Cell-based Therapy:*
625 *Advantages and Disadvantages*. Dev Reprod, 2017. **21**(1): p. 1-10.
- 626 29. Vizoso, F.J., N. Eiro, S. Cid, J. Schneider, and R. Perez-Fernandez, *Mesenchymal Stem Cell*
627 *Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine*. Int J Mol Sci,
628 2017. **18**(9).
- 629 30. Das, C.K., B.C. Jena, I. Banerjee, S. Das, A. Parekh, S.K. Bhutia, and M. Mandal, *Exosome as a*
630 *Novel Shuttle for Delivery of Therapeutics across Biological Barriers*. Molecular pharmaceuticals,
631 2019. **16**(1): p. 24-40.
- 632 31. Samaeekia, R., B. Rabiee, I. Putra, X. Shen, Y.J. Park, P. Hematti, M. Eslani, and A.R. Djalilian,
633 *Effect of Human Corneal Mesenchymal Stromal Cell-derived Exosomes on Corneal Epithelial*

- 634 *Wound Healing*. Investigative Ophthalmology & Visual Science, 2018. **59**(12).
- 635 32. Tao, H., X. Chen, H. Cao, L. Zheng, Q. Li, K. Zhang, Z. Han, Z.C. Han, Z. Guo, Z. Li, and L. Wang,
636 *Mesenchymal Stem Cell-Derived Extracellular Vesicles for Corneal Wound Repair*. Stem Cells Int,
637 2019. **2019**: p. 5738510.
- 638 33. Mead, B. and S. Tomarev, *Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes
639 Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms*. Stem cells
640 translational medicine, 2017. **6**(4): p. 1273-1285.
- 641 34. Lee, R.C., R.L. Feinbaum, and V. Ambros, *The C. elegans heterochronic gene lin-4 encodes small
642 RNAs with antisense complementarity to lin-14*. Cell, 1993. **75**(5): p. 843-854.
- 643 35. Lee, R.C. and V. Ambros, *An extensive class of small RNAs in Caenorhabditis elegans*. Science,
644 2001. **294**(5543): p. 862-4.
- 645 36. Inukai, S., Z. Pincus, A. de Lencastre, and F.J. Slack, *A microRNA feedback loop regulates global
646 microRNA abundance during aging*. Rna, 2018. **24**(2): p. 159-172.
- 647 37. Rupaimoole, R. and F.J. Slack, *MicroRNA therapeutics: towards a new era for the management
648 of cancer and other diseases*. Nat Rev Drug Discov, 2017. **16**(3): p. 203-222.
- 649 38. Nazari-Shafti, T.Z., S. Neuber, A. Garcia Duran, Z. Xu, E. Beltsios, M. Seifert, V. Falk, and C. Stamm,
650 *Human mesenchymal stromal cells and derived extracellular vesicles: Translational strategies
651 to increase their proangiogenic potential for the treatment of cardiovascular disease*. Stem
652 Cells Transl Med, 2020.
- 653 39. Liang, Y.C., Y.P. Wu, X.D. Li, S.H. Chen, X.J. Ye, X.Y. Xue, and N. Xu, *TNF- α -induced exosomal miR-
654 146a mediates mesenchymal stem cell-dependent suppression of urethral stricture*. J Cell
655 Physiol, 2019. **234**(12): p. 23243-23255.
- 656 40. Han, Z., Y. Chen, Y. Zhang, A. Wei, J. Zhou, Q. Li, and L. Guo, *MiR-21/PTEN Axis Promotes Skin
657 Wound Healing by Dendritic Cells Enhancement*. J Cell Biochem, 2017. **118**(10): p. 3511-3519.
- 658 41. Zhang, Y., F. Yuan, L. Liu, Z. Chen, X. Ma, Z. Lin, and J. Zou, *The Role of the miR-21/SPRY2 Axis in
659 Modulating Proangiogenic Factors, Epithelial Phenotypes, and Wound Healing in Corneal
660 Epithelial Cells*. Invest Ophthalmol Vis Sci, 2019. **60**(12): p. 3854-3862.
- 661 42. Jafari, M., E. Ghadami, T. Dadkhah, and H. Akhavan-Niaki, *PI3k/AKT signaling pathway:
662 Erythropoiesis and beyond*. J Cell Physiol, 2019. **234**(3): p. 2373-2385.
- 663 43. Dalirfardouei, R., A. Gholoobi, M. Vahabian, E. Mahdipour, and F. Afzaljavan, *Therapeutic role
664 of extracellular vesicles derived from stem cells in cutaneous wound models: A systematic
665 review*. Life sciences, 2021. **273**: p. 119271.
- 666 44. Alzahrani, A.S., *PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside*. Seminars in
667 cancer biology, 2019. **59**: p. 125-132.
- 668 45. Jiang, Q.W., D. Kaili, J. Freeman, C.Y. Lei, B.C. Geng, T. Tan, J.F. He, Z. Shi, J.J. Ma, Y.H. Luo, H.
669 Chandler, and H. Zhu, *Diabetes inhibits corneal epithelial cell migration and tight junction
670 formation in mice and human via increasing ROS and impairing Akt signaling*. Acta Pharmacol
671 Sin, 2019. **40**(9): p. 1205-1211.
- 672 46. Leszczynska, A., M. Kulkarni, A.V. Ljubimov, and M. Saghizadeh, *Exosomes from normal and
673 diabetic human corneolimbic keratocytes differentially regulate migration, proliferation and
674 marker expression of limbal epithelial cells*. Sci Rep, 2018. **8**(1): p. 15173.
- 675 47. Li, J., X. Qi, X. Wang, W. Li, Y. Li, and Q. Zhou, *PTEN Inhibition Facilitates Diabetic Corneal
676 Epithelial Regeneration by Reactivating Akt Signaling Pathway*. Transl Vis Sci Technol, 2020.
677 **9**(3): p. 5.

- 678 48. Cao, L.Q., X.W. Yang, Y.B. Chen, D.W. Zhang, X.F. Jiang, and P. Xue, *Exosomal miR-21 regulates*
679 *the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth*. *Mol Cancer*,
680 2019. **18**(1): p. 148.
- 681 49. Li, X., Y. Dai, and J. Xu, *MiR-21 promotes pterygium cell proliferation through the PTEN/AKT*
682 *pathway*. *Mol Vis*, 2018. **24**: p. 485-494.
- 683 50. Liu, H.Y., Y.Y. Zhang, B.L. Zhu, F.Z. Feng, H. Yan, H.Y. Zhang, and B. Zhou, *miR-21 regulates the*
684 *proliferation and apoptosis of ovarian cancer cells through PTEN/PI3K/AKT*. *Eur Rev Med*
685 *Pharmacol Sci*, 2019. **23**(10): p. 4149-4155.
- 686 51. Worby, C.A. and J.E. Dixon, *PTEN*. *Annu Rev Biochem*, 2014. **83**: p. 641-69.
- 687 52. Boosani, C.S., P. Gunasekar, and D.K. Agrawal, *An update on PTEN modulators - a patent review*.
688 *Expert Opin Ther Pat*, 2019. **29**(11): p. 881-889.
- 689 53. Sun, Y., X. Yao, Q.J. Zhang, M. Zhu, Z.P. Liu, B. Ci, Y. Xie, D. Carlson, B.A. Rothermel, Y. Sun, B.
690 Levine, J.A. Hill, S.E. Wolf, J.P. Minei, and Q.S. Zang, *Beclin-1-Dependent Autophagy Protects*
691 *the Heart During Sepsis*. *Circulation*, 2018. **138**(20): p. 2247-2262.
- 692 54. Zhang, L., S. Zhang, J. Yao, F.J. Lowery, Q. Zhang, W.C. Huang, P. Li, M. Li, X. Wang, C. Zhang, H.
693 Wang, K. Ellis, M. Cheerathodi, J.H. McCarty, D. Palmieri, J. Saunus, S. Lakhani, S. Huang, A.A.
694 Sahin, K.D. Aldape, P.S. Steeg, and D. Yu, *Microenvironment-induced PTEN loss by exosomal*
695 *microRNA primes brain metastasis outgrowth*. *Nature*, 2015. **527**(7576): p. 100-104.
- 696 55. Wise, H.M., M.A. Hermida, and N.R. Leslie, *Prostate cancer, PI3K, PTEN and prognosis*. *Clin Sci*
697 (Lond), 2017. **131**(3): p. 197-210.
- 698 56. Romero-Pozuelo, J., G. Figlia, O. Kaya, A. Martin-Villalba, and A.A. Teleman, *Cdk4 and Cdk6*
699 *Couple the Cell-Cycle Machinery to Cell Growth via mTORC1*. *Cell Rep*, 2020. **31**(2): p. 107504.
- 700 57. Ma, L.L., D.W. Wang, X.D. Yu, and Y.L. Zhou, *Tangeretin induces cell cycle arrest and apoptosis*
701 *through upregulation of PTEN expression in glioma cells*. *Biomed Pharmacother*, 2016. **81**: p.
702 491-496.

703